Skip to main content
SpringerLink
Log in

Hochdosistherapie bei hämatologischen Neoplasien

  • Chapter
Therapiekonzepte Onkologie

  • 68 Accesses

Zusammenfassung

Für das Konzept der hochdosierten antineoplastischen Therapie maligner hämatologischer Systemkrankheiten sprechen vor allem folgende Gründe:

  1. 1.

    Unter in vitro Bedingungen und in experimentellen in vivo Systemen besitzen Zytostatika (insbesondere alkylierende Substanzen) und Radiotherapie steil verlaufende Dosis-Wirkungs-Beziehungen bei einer Vielzahl neoplastischer Zellarten der blutbildenden Organe.

  2. 2.

    Die bei „konventionell” dosierter antineoplastischer Therapie Dosislimitierende Hämatotoxizität wird als therapeutische Wirkung nutzbar, weil durch die Übertragung Patienten-eigener oder allogener hämatopoetischer Stammzellen nach einer Hochdosistherapie (HDT) die Regeneration der physiologischen Hämatopoese sichergestellt werden kann.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Wissenschaftlicher Beirat der Bundesärztekammer (1997) Richtlinien zur Transplantation peripherer Blutstammzellen. Deutsches Ärzteblatt 94:C-1177–1185

    Google Scholar 

  2. Jurcic JG, Miller WH, De Blasio Jr A et al. (1996) Prognostic significance of minimal residual disease and PML/RAR-α isoform type: long-term follow-up in acute promyelocytic leukemia (APL). Blood 88:635a, Abstr 2529

    Google Scholar 

  3. Creutzig U, Schrappe M (1996) Akute Leukämien im Kindesalter. Klassifikation-Diagnose-Therapie-Prognose. Internist 37:982–993

    PubMed  CAS  Google Scholar 

  4. Appelbaum FR, Fisher LD, Thomas ED et al. (1988) Chemotherapie v marrow transplantation for adults with acute nonlymphocytic leukemia: a five year follow up. Blood 72:179–184

    PubMed  CAS  Google Scholar 

  5. Büchner T, Hiddemann W, Wörmann B et al. (1995) Allogeneic bone marrow transplantation versus prolonged chemotherapy after intensive induction in patients with acute myeloid leukemia (AML): a study by AMLCG. Proc ASCO 13:336

    Google Scholar 

  6. Cassileth PA, Lynch E, Hines JD et al. (1992) Varying intensity of postremission therapy in acute myeloid leukemia. Blood 79:1924–1930

    PubMed  CAS  Google Scholar 

  7. Ferrant A, Doyen C, Delannoy A et al. (1991) Allogeneic or autologous bone marrow transplantation for acute non lymphocytic leukemia in first remission. Bone Marrow Transplant 7:303–309

    PubMed  CAS  Google Scholar 

  8. Gratwohl A, Ljungman P, de Witte T et al. (1992) Bone marrow transplantation for acute myeloid leukemia: the EBMT experience. A prospective analysis from HLA typing. The EMBT Leukemia Working Party. Leukemia 6 (Suppl 2) : 110–113

    PubMed  Google Scholar 

  9. Reiffers J, Stoppa AM, Rigal Huguet F et al. (1991) Allogeneic versus autologous bone marow transplantation versus chemotherapy for treatment of acute myeloid leukemia in first complete remission (BGM 84 and BGMT 87 studies). The BGMT Group. Bone Marrow Transplant 7 (Suppl 2) : 36

    PubMed  Google Scholar 

  10. Zittoun R, Mandelli F, Willemze R et al. (1995) Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N Engl J Med 332:217–223

    Article  PubMed  CAS  Google Scholar 

  11. Link H, Ehninger G, Schönrock-Nabulsi et al. (1996) Allogeneic bone marrow transplantation compared with high-dose Ara-C postremission therapy in acute myeloid leukemia. Blood 88 (Suppl 1) :684a, Abstr 2723

    Google Scholar 

  12. Ravindranath Y, Yeager AM, Chang MN et al. (1996) Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 334:1428–1434

    Article  PubMed  CAS  Google Scholar 

  13. Biggs JC, Horowitz MM, Gale RP et al. (1992) Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 80:1090–1093

    PubMed  CAS  Google Scholar 

  14. Clift RA, Buckner CD, Thomas ED et al. (1987) The treatment of acute non lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant 2:243–258

    PubMed  CAS  Google Scholar 

  15. Ehninger G, Schuler U, Schaefer UW (1991) Fortschritte der Knochenmarktransplantation in der Bundesrepublik Deutschland. Dtsch Ärztebl 88:B1005–1009

    Google Scholar 

  16. Gale RP, Horowitz MM, Bortin MM (1989) IBMTR analysis of bone marrow transplants in acute leukaemia. Advisory Committee of the International Bone Marrow Transplant Registry (IBMTR). Bone Marrow Transplant 4(Suppl 3): 83–84

    PubMed  Google Scholar 

  17. Gratwohl A, Ljungman P, de Witte T et al. (1992) Bone marrow transplantation for acute myeloid leukemia: the EBMT experience. A prospective analysis from HLA typing. The EMBT Leukemia Working Party. Leukemia 6 (Suppl 2) : 110–113

    PubMed  Google Scholar 

  18. Kernan NA, Bartsch G, Ash RC et al. (1993) Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 328:593–602

    Article  PubMed  CAS  Google Scholar 

  19. Gorin N (1995) High-dose therapy for acute myelocytic leukemia. In: Armitage JO, Antman KH (Hrsg.): High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem cells, Williams & Wilkins, Baltimore, 635–678

    Google Scholar 

  20. Gorin NC, Labopin M, Meloni G et al. (1991) Autologous bone marrow transplantation for acute myeloblastic leukemia in Europe: further evidence of the role of marrow purging by mafosfamide. European Cooperative Group for Bone Marrow Transplantation (EBMT). Leukemia 5:896–904

    PubMed  CAS  Google Scholar 

  21. Runde V, De Witte T, Aul C et al. (1997) Myelodysplastic syndromes or leukemia following MDS treated with allogeneic bone marrow transplantation: a survey of the working party on chronic leukemia of the European Cooperative Group for Blood and Marrow Transplantation. In: Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J, Creutzig U (Hrsg.): Acute Leukemias VI. Prognostic Factors and Treatment Strategies. Springer, Berlin Heidelberg, 929–933

    Google Scholar 

  22. Wattel E, Solary E, Caillot D et al. (1996) Prospective study of autologous bone marrow (ABMT) or peripheral blood stem cell (ABSCT) transplantation after intensive chemotherapy in myelodysplastic syndromes. Blood 88 (Suppl 1) : 130a, Abstr 507

    Google Scholar 

  23. Dicke KA, Hoelzer D, Gorin NC et al. (1993) The role of bone marrow transplantation in adult acute lymphocytic leukemia. Ann Oncol 4:581–5909

    Article  Google Scholar 

  24. Barrett AJ, Horowitz MM, Ash RC et al. (1992) Bone marrow transplantation for Philadelphia-Chromosome positive acute lymphoblastic leukemia. Blood 79:3067–3070

    PubMed  CAS  Google Scholar 

  25. Hoelzer D, Gökbuget N, Arnold R et al. (1996) Akute lymphatische Leukämie des Erwachsenen. Diagnostik, Risikogruppen und Therapie. Internist 37:994–1007

    PubMed  CAS  Google Scholar 

  26. Doney K, Fisher LD, Appelbaum FR et al. (1991) Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free-survival. Bone Marrow Transplant 7:453–459

    PubMed  CAS  Google Scholar 

  27. Gratwohl A, Hermans J, Barrett AJ et al. (1990) Allogeneic bone marrow transplantation for leukemia in Europe: Regiona differences. Report from the leukemia working party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 5:159–162

    PubMed  CAS  Google Scholar 

  28. Horowitz MM, Messerer D, Hoelzer D et al. (1991) Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med 115:13–18

    Article  PubMed  CAS  Google Scholar 

  29. Arnold R, Bunjes D, Einsele H et al. (1996) Long-term results of BMT in high risk adult ALL patients treated in the German ALL studies. Blood 88(Suppl 1) :614a, Abstr. 2446

    Google Scholar 

  30. Dopfer R, Henze G, Bender-Götze C et al. (1991) Allogeneic bone marrow transplantation for childhood acute lymphoblastic leukemia in second remission after intensive primary and relapse therapy according to the BFM- and CoALL protocols: Results of the German Cooperative Study. Blood 78:2780–2784

    PubMed  CAS  Google Scholar 

  31. Martin H, Atta J, Zumpe P et al. (1995) Purging of peripheral blood stem cells yields BCR-ABL negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia. Exp Hematol 23:1612–1618

    PubMed  CAS  Google Scholar 

  32. McGlave P (1990) Bone marrow transplants in chronic myelogenous leukemia: an overview of determinants of survival. Semin Hematol 27(Suppl 4) : 23–30

    PubMed  CAS  Google Scholar 

  33. Ringden O, Horowitz MM, Gale RP et al. (1993) Outcome after allogeneic bone marrow transplant for leukemia in older adults. JAMA 270:57–60

    Article  PubMed  CAS  Google Scholar 

  34. Bortin MM, Horowitz MM, Mrsic M, Rimm AA, Sobocinski KA (1991) Progress in bone marrow transplantation for leukemia: a preliminary report from the Advisory Committee of the International Bone Marrow Transplant Registry. Transplant Proc 23(Pt l):61–62

    PubMed  CAS  Google Scholar 

  35. McGlave P, Bartsch G, Anasetti C et al. (1993) Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 81:543–550

    PubMed  CAS  Google Scholar 

  36. Goldman JM, Szydlo R, Horowitz MM et al. (1993) Choice of pretransplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 82:2235–2238

    PubMed  CAS  Google Scholar 

  37. Beelen DW, Graeven U, Sayer HG et al. (1993) Improved results of allogeneic marrow transplantation for chronic phase chronic myeloid leukemia. Ann Hematol 67 (Suppl): 24

    Google Scholar 

  38. Goldman JM, Gale RP, Horowitz MM et al. (1988) Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 108:806–814

    Article  PubMed  CAS  Google Scholar 

  39. Gratwohl A, Hermans J, Niederwieser D et al. (1993) Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transplant 12:509–516

    PubMed  CAS  Google Scholar 

  40. Marks DI, Hughes TP, Szydlo R et al. (1992) HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. Br J Haematol 81:383–390

    Article  PubMed  CAS  Google Scholar 

  41. Thomas ED, Gift RA (1989) Indications for marrow transplantation in chronic myelogenous leukemia. Blood 73:861–864

    PubMed  CAS  Google Scholar 

  42. Hughes TP, Grigg A, Szer J et al. (1996) Mobilization of predominantly Ph-negative blood progenitors using cyclophosphamide and lenograstim in early chronic phase CML: correlation with Sokal prognostic index and hematological control premobilisation. Blood 88:235 a, Abstr 927

    Google Scholar 

  43. Barnett MJ, Eaves CJ, Phillips GL et al. (1994) Allografting with cultured marrow in chronic myeloid leukemia. Results of a pilot study. Blood 84:724–732

    PubMed  CAS  Google Scholar 

  44. Press O, Fisher R, Dalla-Favera R (1996) Aggressive Non-Hodgkin’s Lymphomas. In: Schechter P, McArthur JR (Hrsg.): Hematology 1996 — The Education Program of the American Society of Hematology, 48–61

    Google Scholar 

  45. Philip T, Guglielmi C, Hagenbeek A et al. (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapsese of chemotherapy-sensitive Non-Hodgkin’s lymphoma. N Engl J Med 333:1540–1545

    Article  PubMed  CAS  Google Scholar 

  46. Schmitz N, Linch DC, Goldstone AH et al. (1996) Randomized trial of figrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet 347:353–357

    Article  PubMed  CAS  Google Scholar 

  47. Kaiser U, Trümper L, Pfreundschuh M, Havemann K (1997) Behandlung aggressiver Non-Hodgkin-Lymphome. Internist 38:135–142

    PubMed  CAS  Google Scholar 

  48. Michallet M, Archimbaud E, Bandini E et al. (1996) HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. Ann Int Med 124:311–315

    Article  PubMed  CAS  Google Scholar 

  49. Hiddemann W, Unterhalt M, Sack H (1997) Aktueller Stand in der Therapie von follikulären Keimzentrumslymphomen und Mantelzeil-Lymphomen. Internist 38:122–134

    PubMed  CAS  Google Scholar 

  50. Haas R, Brittinger G, Meusers P et al. (1996) Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 10: 1975–1979

    PubMed  CAS  Google Scholar 

  51. Dreger P, Kuse R, von Neuhoff P et al. (1996) Early stem cell transplantation for chronic lymphocytic leukemia. Blood 88:125 a, Abstr 487

    Google Scholar 

  52. Vose JM, Phillips GL, Armitage JO (1995) Autologous bone marrow transplantation for Hodgkin’s disease. In: Armitage JO, Antman KH (Hrsg.): High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem cells, Williams & Wilkins, Baltimore, 744–756

    Google Scholar 

  53. Gahrton G, Tura S, Ljungman P et al. (1991) Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 325:1267–1272

    Article  PubMed  CAS  Google Scholar 

  54. Gahrton G, Tura S, Ljungman P et al. (1995) Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 13:1312–1322

    PubMed  CAS  Google Scholar 

  55. Verdonck LF, Lokhorst HM, Dekker AW et al. (1996) Graft-versus-myeloma effect in two cases. Lancet 347:800–802

    Article  PubMed  CAS  Google Scholar 

  56. Björkstrand B, Ljungman P, Svensson H et al. (1996) Allogenic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group of Blood and Marrow Transplantation. Blood 88:4711–4718

    PubMed  Google Scholar 

  57. Attal M, Harousseau JL, Stoppa AM et al. (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91–97

    Article  PubMed  CAS  Google Scholar 

  58. Vesole DH, Jagannath S, Tricot G, Barlogie B (1995) Intensive therapy with hematopoietic stem cell transplantation for the treatment of multiple myeloma. In: Armitage JO, Antman KH (Hrsg.): High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem cells, Williams & Wilkins, Baltimore, 728–743

    Google Scholar 

  59. Harousseau JL, Attal M, Divine M et al. (1995) Comparison of autologous bone marrow transplantation and peripheral blood stem cell transplantation after first remission induction treatment in multiple myeloma. Bone Marrow Transpl 15:963–969

    CAS  Google Scholar 

Download references

Authors
  1. D. W. Beelen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. U. W. Schaefer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Beelen, D.W., Schaefer, U.W. (1998). Hochdosistherapie bei hämatologischen Neoplasien. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10493-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10493-4_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63821-6

  • Online ISBN: 978-3-662-10493-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation